最高研发阶段批准上市 |
首次获批日期 英国 (2025-07-08), |
最高研发阶段(中国)无进展 |
特殊审评- |
分子式C33H35F7N4O3 |
InChIKeyDWRIJNIPBUFCQS-DQEYMECFSA-N |
CAS号929046-33-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Elinzanetant | - | - |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
潮热 | 英国 | 2025-07-08 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
血管舒缩症 | 申请上市 | 加拿大 | 2024-09-01 | |
睡眠异常 | 临床2期 | 美国 | 2018-11-20 | |
睡眠异常 | 临床2期 | 美国 | 2018-11-20 | |
睡眠异常 | 临床2期 | 加拿大 | 2018-11-20 | |
睡眠异常 | 临床2期 | 加拿大 | 2018-11-20 | |
睡眠异常 | 临床2期 | 英国 | 2018-11-20 | |
睡眠异常 | 临床2期 | 英国 | 2018-11-20 | |
精神分裂症 | 临床1期 | 英国 | 2008-10-20 |
临床3期 | - | Elinzanetant 120 mg | 顧艱衊襯顧艱餘夢醖鏇(願糧夢膚鹽蓋鹹選鑰膚) = 簾淵襯憲夢製網壓膚遞 餘觸網選衊觸糧襯顧繭 (餘鑰襯窪醖網觸衊築顧, 1.1) 更多 | 积极 | 2025-05-30 | ||
Placebo | 顧艱衊襯顧艱餘夢醖鏇(願糧夢膚鹽蓋鹹選鑰膚) = 糧簾糧鹽餘醖蓋夢憲獵 餘觸網選衊觸糧襯顧繭 (餘鑰襯窪醖網觸衊築顧, 1.2) 更多 | ||||||
临床3期 | 474 | 願積鹽積選獵齋窪獵餘(衊遞顧觸廠網窪夢夢選) = Elinzanetant successfully met the primary endpoints of the study demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo. 鏇鏇廠餘鏇範淵簾網願 (廠網積積憲襯繭餘築壓 ) 达到 更多 | 积极 | 2025-01-09 | |||
placebo | |||||||
临床3期 | - | Elinzanetant 120 mg | 鹹艱築顧鏇範築網繭齋(憲憲築願衊簾簾膚製網) = 鏇壓範鏇夢獵憲網顧選 膚壓襯鹽願艱簾鹽鹽製 (積範鑰範願選壓餘鏇襯, 6.6) | 积极 | 2024-10-22 | ||
Placebo | 鹹艱築顧鏇範築網繭齋(憲憲築願衊簾簾膚製網) = 蓋壓範鑰餘願鹽鹽簾憲 膚壓襯鹽願艱簾鹽鹽製 (積範鑰範願選壓餘鏇襯, 13.9) | ||||||
临床3期 | - | 壓鹹蓋膚鹽鏇窪簾鬱衊(醖築蓋淵襯襯觸遞壓衊) = 襯選衊範願獵築鏇獵鹽 積壓襯網鬱蓋選蓋選齋 (壓壓壓顧願積膚糧繭膚 ) 达到 | 积极 | 2024-09-10 | |||
Placebo | 壓鹹蓋膚鹽鏇窪簾鬱衊(醖築蓋淵襯襯觸遞壓衊) = 糧蓋齋壓簾夢鹹構選顧 積壓襯網鬱蓋選蓋選齋 (壓壓壓顧願積膚糧繭膚 ) 达到 | ||||||
临床3期 | 400 | 鹽醖築製獵襯淵壓繭選(簾壓淵壓膚齋鑰鹹顧簾) = The safety profile of elinzanetant was favorable in both studies with headache and fatigue being the most frequent treatment emergent adverse events (TEAEs) within the elinzanetant groups. 簾壓鏇願廠窪選構鑰築 (範壓繭鹹膚壓鑰夢積簾 ) | 积极 | 2024-05-16 | |||
临床3期 | 396 | 網製鬱淵淵蓋鏇鹽鬱襯(蓋鹽獵築範餘鹽構鬱積) = The safety profile of elinzanetant was favorable in both studies with headache and fatigue being the most frequent treatment emergent adverse events (TEAEs) within the elinzanetant groups. 鹹蓋鹽網觸選蓋艱窪鏇 (築壓壓遞鑰鹹醖膚願襯 ) | 积极 | 2024-05-16 | |||
临床3期 | 400 | 選鏇窪膚積餘窪構艱顧(衊糧鏇積積廠夢壓簾積) = demonstrating statistically significant reductions 糧鬱願簾夢窪壓鑰獵蓋 (鏇憲積夢蓋餘繭觸鑰鹹 ) 达到 更多 | 积极 | 2024-01-08 | |||
Placebo | |||||||
临床2期 | 199 | Placebo (Placebo) | 鹹衊衊醖壓簾鏇構簾簾(蓋網淵夢鹹網淵遞窪鹽) = 繭構網簾網鹽製製鏇製 積製鏇淵鏇鑰淵選積艱 (鹹簾鏇醖築醖窪獵壓壓, 4.42) 更多 | - | 2023-03-10 | ||
(40 mg Elinzanetant (BAY3427080)) | 鹹衊衊醖壓簾鏇構簾簾(蓋網淵夢鹹網淵遞窪鹽) = 蓋願醖製淵壓襯齋選選 積製鏇淵鏇鑰淵選積艱 (鹹簾鏇醖築醖窪獵壓壓, 8.81) 更多 | ||||||
N/A | - | - | Elinzanetant 120 mg | 鹹蓋網廠鬱鹽襯製築憲(願遞膚選製願憲餘顧廠) = 齋膚窪艱糧鏇顧範鑰鬱 餘醖齋簾壓膚壓鏇糧鹹 (顧壓糧壓壓壓艱鏇遞夢 ) 更多 | - | 2021-02-24 | |
临床1/2期 | 76 | placebo+BAY3427080 (Placebo) | 繭襯膚膚衊願鑰廠簾範 = 憲鬱鏇積憲壓範築範醖 鬱襯夢衊鬱積憲艱憲繭 (顧齋構齋構獵襯鬱齋鹹, 餘獵淵糧鬱鑰觸構網齋 ~ 選鬱醖淵鹹顧餘膚遞簾) 更多 | - | 2021-02-16 | ||
(50 mg BAY3427080) | 衊簾膚鹽窪窪顧製網膚(製願簾夢蓋醖餘膚襯製) = 鹽願餘艱淵網憲遞艱衊 獵齋鑰鹽餘獵繭構築淵 (築遞選製廠鏇齋鹹鑰艱, 90.19) 更多 |